TY - JOUR ID - 7897 TI - The Role of EDD (Exercise Capacity, Dyspnea, and Diffusing Capacity of Lungs for Carbon Monoxide) Index in Pulmonary Fibrosis Secondary to Scleroderma JO - Journal of Cardio-Thoracic Medicine JA - JCTM LA - en SN - 2345-2447 AU - Shariaati Sarabai, Jaleh AU - Attaran, Davood AU - M.lari, Shahrzad AU - Nazari, Pouya AU - Akhlaghi, Saeid AU - Bahadori, Arya AD - Rheumatologist, Rheumatology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. AD - Pulmonologist, Lung Disease Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran AD - General Practitioner, Lung Disease Research Center, Mashhad University of Medical Sciences, Mashhad, Iran AD - Statisticien, Vice Chancellery of Research, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran AD - Radiologist, Lung Disease Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Y1 - 2016 PY - 2016 VL - 4 IS - 4 SP - 516 EP - 521 KW - High Resolution CT Scan KW - Lung Function Tests KW - Pulmonary Fibrosis KW - Scleroderma DO - 10.22038/jctm.2016.7897 N2 - Introduction: Pulmonary involvement secondary to Systemic Sclerosis (SSc) is the major cause of morbidity and mortality in SSc patients. We designed this study to determine the correlation of important lung function parameters with lung High Resolution CT (HRCT) scan findings. Materials and Methods: Thirty–two consecutive diffuse SSc patients with pulmonary fibrosis were enrolled in this cross-sectional study. Patients with pulmonary fibrosis secondary to other causes, previous restrictive lung disease, and history of smoking were excluded. Complete lung function evaluation was performed. The EDD (Exercise capacity, Dyspnea, and Diffusing capacity of lungs for carbon monoxide) index was determined. The Warrick score was calculated based on lung HRCT findings. Results: The mean age of the patients was 39.18 years ±9.39 (SD).Seventeen (53%) patients were in EDD stage 1 (score: 0≤score≤3), 9 patients (28%) in stage 2 (3